Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $23.
September 27, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Inozyme Pharma and maintained a price target of $23.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $23 price target indicates a positive outlook for Inozyme Pharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100